Table 2.
Pharmacokinetic parameters for eribulin mesylate alone or co-administered with rifampicin: pharmacokinetic population
| Parameter Actual values | Eribulin mesylate | Eribulin mesylate with rifampicin |
|---|---|---|
| AUC(0,∞) (ng ml−1 h) | 757 (264) | 846 (326) |
| Cmax (ng ml−1) | 371 (164) | 360 (168) |
| tmax (h) | 0.17 (0.08–0.32) | 0.10 (0.05–0.37) |
| t1/2 (h) | 40.4 (9.67) | 36.6 (8.25) |
| CL (l h−1) | 3.41 (1.31) | 3.18 (1.38) |
| Vss (l) | 134 (42.7) | 109 (38.9) |
Eribulin mesylate dose was 1.4 mg m−2 (n = 11 both). Data are shown as mean (SD) except for tmax which are median (range) values. AUC(0,∞), area under the concentration−time curve from zero (pre-dose) extrapolated to infinity; CL, systemic clearance; Cmax, maximum observed plasma concentration; t1/2, terminal half-life; tmax, time to maximum observed plasma concentration; Vss, volume of distribution at steady state.